<DOC>
	<DOC>NCT00800865</DOC>
	<brief_summary>A study to evaluate biomarkers of cancer (context-specific sensitizers) in the skin of participants already receiving cytotoxic therapy. Additional blood and urine samples will be collected for phosphorylated Histone 2AX (Î³H2AX) and renal toxicity biomarker testing, respectively.</brief_summary>
	<brief_title>A Study to Evaluate Biomarkers in Patients With Solid Tumors (0000-097)(COMPLETED)</brief_title>
	<detailed_description />
	<criteria>Participant has solid tumor that will be treated with one of the following treatments: Gemcitabine monotherapy Cisplatin monotherapy Carboplatin monotherapy Gemcitabine and cisplatin combination therapy Gemcitabine and erlotinib combination therapy Gemcitabine and carboplatin combination therapy Cisplatin and vinorelbine combination therapy Cisplatin and pemetrexed combination therapy Carboplatin and vinorelbine combination therapy Carboplatin and pemetrexed combination therapy Participant has had recent cancer treatments including chemotherapy or radiation Participant has been in an investigational study within the last 30 days Participant has a history of drug or alcohol abuse Participant is Human Immunodeficiency Virus (HIV) positive or has a history of Hepatitis B or C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>